Clinical Assessment of a Novel Microprobe Array Continuous Glucose Monitor for Type 1 Diabetes

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-11-30

Study Completion Date

2018-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to assess the safety and efficacy of the Imperial College Microprobe Array Continuous Glucose Sensor in healthy volunteers and in subjects with type 1 diabetes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Use of Continuous Glucose Monitoring Devices Among People Living With Type 1 Diabetes in Kenya.

NCT05944731

Type 1 Diabetes

NOT_YET_RECRUITING NA

Impact on Hypoglycaemia Awareness of Real Time CGM and Intermittent Continuous Glucose Data

NCT03028220

Type 1 Diabetes Mellitus With Hypoglycemia Impaired Awareness of Hypoglycemia Type1diabetes

COMPLETED NA

An Evaluation of Novel Glucose Sensing Technology on Hypoglycaemia in Type 1 Diabetes (IMPACT)

NCT02232698

Type 1 Diabetes Mellitus

COMPLETED NA

Evaluation of Glucose Monitoring Methods: Characterizing Glycemic Control in Subjects With Diabetes

NCT00805506

Diabetes

COMPLETED

Standardized Procedure for the Assessment of New-to-market Continuous Glucose Monitoring Systems

NCT01751932

Diabetes Mellitus

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Continuous knowledge of ambient glucose levels will be of benefit to patients with T1DM, especially those with troublesome hypoglycaemia. Existing monitors require skin puncture to access interstitial fluid and sense its glucose content. Despite their clinical benefits, their use is associated with discomfort and their accuracy is questionable in hypoglycaemia. The development of a painless continuous glucose monitor is regarded as the top research priority by patients with diabetes. A novel continuous glucose monitoring device has been developed at Imperial College based on microprobe technology. It consists of a small, wearable patch (\~1 cm2), the size of a conventional postage stamp, containing microscopic projections (microprobes) that penetrate only the outermost skin layer. It accesses interstitial fluid to sense its glucose content without stimulating skin nerve fibres or reaching blood vessels within skin layers. The microprobe surface has the consistency of sandpaper. It is pushed into the skin with an applicator allowing it to penetrate through the skin layers and access the interstitial fluid in a minimally invasive manner. The device is disposable and optimum performance will be assessed over five days. The advantages of microprobe technology have been demonstrated in other clinical situations and include painless insertion, absence of bleeding and a low infection risk. The large surface area utilised in our microprobe device has the potential to improve device sensitivity and accuracy. Pre-clinical validation tests have demonstrated the ability of the device to respond accurately to variable glucose concentrations and to penetrate the outermost skin layer without fracture. We aim now to further develop the device through clinical studies in non-diabetic subjects and subjects with type 1 diabetes to allow painless accurate continuous glucose monitoring.

The study will recruit 16 non-diabetic subjects and 20 subjects with type 1 diabetes.

It will be conducted over four phases;

oPhase 1 will assess safety, as a primary outcome, and efficacy, as a secondary outcome, in non-diabetic subjects over six hours in the clinical research facility where the device will be fitted and a cannula inserted for venous sampling every 15 minutes to measure venous blood glucose (YSI). Safety will be assessed with regards to skin inflammation and pain. Efficacy will be assessed in this phase by assessing magnitude of current measured by the microprobe array sensor and comparison of measured ISF glucose concentrations to simultaneous venous blood glucose samples (YSI).

oPhase 2 will also assess safety, as a primary outcome, and efficacy, as a secondary outcome, in non-diabetic subjects over a period of 24 hours. The first six hours in the clinical research facility (same as phase 1), then subject will be allowed to go home with the device to assess safety over that period.

oPhase 3 aims to assess efficacy of the device as a primary outcome and safety as a secondary outcome. This will be in subjects with type 1 diabetes over 24 hours as inpatients. Efficacy will be assessed mechanically (by the ability to penetrate the stratum corneum) and functionally (by the ability to accurately sense ISF glucose). The derived ISF glucose levels will be compared with simultaneous venous glucose samples (YSI) and with a commercially available CGM device (iPro2, Medtronic). Assessment of microprobe penetration of the stratum corneum will be performed using confocal microscopy, optical coherence tomography and in skin biopsies.

oPhase 4 aims to assess efficacy of the device as a primary outcome and safety as a secondary outcome. This will be in subjects with type 1 diabetes over 5 days in ambulatory situation. Efficacy will be assessed by comparing microprobe sensor derived ISF glucose levels against ISF glucose levels measured using a commercially available CGM device (iPro2, Medtronic).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Microprobe Glucose Sensor Phase 1

The microprobe array continuous glucose sensor will be applied to healthy volunteers for 6 hours

Group Type EXPERIMENTAL

Microprobe glucose sensor

Intervention Type DEVICE

Assessment of safety and accuracy of a novel continuous glucose monitor based on microprobe technology.

Microprobe Glucose Sensor Phase 2

The microprobe array continuous glucose sensor will be applied to healthy volunteers for 24 hours

Group Type EXPERIMENTAL

Microprobe glucose sensor

Intervention Type DEVICE

Assessment of safety and accuracy of a novel continuous glucose monitor based on microprobe technology.

Microprobe Glucose Sensor Phase 3 and 4

The microprobe array continuous glucose sensor will be applied to participants with type 1 diabetes

Group Type EXPERIMENTAL

Microprobe glucose sensor

Intervention Type DEVICE

Assessment of safety and accuracy of a novel continuous glucose monitor based on microprobe technology.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Microprobe glucose sensor

Assessment of safety and accuracy of a novel continuous glucose monitor based on microprobe technology.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Microprobe Array Continuous Glucose Monitor

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• Adults over 18 years of age

* Adults over 18 years of age.
* Diagnosed with Type 1 diabetes for greater than 1 year.
* HbA1c less than or equal to 9.0 % (75 mmol/mol).
* Registered with a General Practitioner.

Exclusion Criteria

* History of upper limb neuropathy or radiculopathy
* History of pre-existing skin condition
* Pregnant or planning pregnancy in next 12 months
* Breastfeeding
* Enrolled in other clinical trials
* uncontrolled concurrent illness
* Have active malignancy or under investigation for malignancy

For phases 3 and 4:

* History of diabetic dermopathy or pre-existing skin condition
* History of upper limb neuropathy or radiculopathy
* Pregnant or planning pregnancy in next 12 months
* Breastfeeding
* Enrolled in other clinical trials
* uncontrolled concurrent illness
* physical or visual impairment preventing sensor's use
* Have active malignancy or under investigation for malignancy

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes